GABITRIL

This brand name is authorized in United States. It is also authorized in Australia, France, Ireland, Lithuania, Poland, Spain, UK.

Active ingredients

The drug GABITRIL contains one active pharmaceutical ingredient (API):

1	Tiagabine hydrochloride monohydrate UNII DQH6T6D8OY - TIAGABINE HYDROCHLORIDE
	Tiagabine is an anti-epileptic drug. Tiagabine is a potent and selective inhibitor of both neuronal and glial GABA uptake, which results in an increase in GABAergic medicated inhibition in the brain.
	Read more about Tiagabine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GABITRIL Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AG06	Tiagabine	N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AG Fatty acid derivatives
Discover more medicines within N03AG06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8221Q, 8222R, 8223T
ES	Centro de información online de medicamentos de la AEMPS	61606, 61607, 61608
FR	Base de données publique des médicaments	60058517, 61089729, 67859994
GB	Medicines & Healthcare Products Regulatory Agency	39019, 39022, 41301
IE	Health Products Regulatory Authority	58523, 58547, 58568
LT	Valstybinė vaistų kontrolės tarnyba	1004263, 1004264, 1007436, 1007437
PL	Rejestru Produktów Leczniczych	100080823, 100080830, 100247298
US	FDA, National Drug Code	63459-402, 63459-404, 63459-412, 63459-416